{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:24:48Z","timestamp":1773246288123,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/wnf.0b013e3181684542","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T07:10:03Z","timestamp":1225350603000},"page":"59-62","source":"Crossref","is-referenced-by-count":28,"title":["Impulse Control Disorders Arising in 3 Patients Treated With Rotigotine"],"prefix":"10.1097","volume":"32","author":[{"given":"Thomas S.","family":"Wingo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Evatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burton","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210203","first-page":"259","article-title":"Mental disorders in Parkinson's disease after treatment with L-dopa.","volume":"40","author":"Rondot","year":"1984","journal-title":"Adv Neurol"},{"issue":"2","key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/jnnp.33.2.188","article-title":"Psychiatric symptoms in parkinsonism.","volume":"33","author":"Mindham","year":"1970","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"R4-1-20210203","first-page":"11","article-title":"Parkinson's disease: a review of cognitive and psychiatric disorders.","volume":"3","author":"Mayeux","year":"1990","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"13","key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.1971.03190260031009","article-title":"Psychiatric side effects of levodopa in man.","volume":"218","author":"Goodwin","year":"1971","journal-title":"JAMA"},{"issue":"pt 1","key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","article-title":"Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.","volume":"29","author":"Lesser","year":"1979","journal-title":"Neurology"},{"key":"R8-1-20210203","first-page":"115","article-title":"Parkinson's disease: drug-induced psychiatric states.","volume":"65","author":"Factor","year":"1995","journal-title":"Adv Neurol"},{"issue":"7","key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1532-5415.1991.tb03627.x","article-title":"Behavioral complications of drug treatment of Parkinson's disease.","volume":"39","author":"Cummings","year":"1991","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease.","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch Neurol"},{"issue":"6","key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.","volume":"11","author":"Klos","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198910000-00002","article-title":"Hypersexuality with antiparkinsonian therapy.","volume":"12","author":"Uitti","year":"1989","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov Disord"},{"issue":"9","key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease.","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"issue":"2","key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archneur.63.2.298-a","article-title":"Gambling and Parkinson disease.","volume":"63","author":"Lu","year":"2006","journal-title":"Arch Neurol"},{"issue":"12","key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/mds.21110","article-title":"Problematic gambling on dopamine agonists: not such a rarity.","volume":"21","author":"Grosset","year":"2006","journal-title":"Mov Disord"},{"issue":"12","key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/mds.21072","article-title":"Prevalence of pathological gambling in patients with Parkinson's disease.","volume":"21","author":"Avanzi","year":"2006","journal-title":"Mov Disord"},{"issue":"11","key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease.","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"issue":"11","key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2165\/00023210-200519110-00006","article-title":"Rotigotine in Parkinson's disease.","volume":"19","author":"Reynolds","year":"2005","journal-title":"CNS Drugs"},{"issue":"suppl 1","key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.65.2_suppl_1.S3","article-title":"A novel dopamine agonist for the transdermal treatment of Parkinson's disease.","volume":"65","author":"Jenner","year":"2005","journal-title":"Neurology"},{"key":"R23-1-20210203","first-page":"S258","article-title":"Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial.","volume":"19","author":"Watts","year":"2004","journal-title":"Mov Disord"},{"key":"R24-1-20210203","first-page":"S93","article-title":"Rotigotine transdermal patch (neupro (r)) is efficacious and safe in patients with early-stage, idiopathic Parkinson's disease, regardless of gender, age, duration and severity of disease. Results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"20","author":"Watts","year":"2005","journal-title":"Mov Disord"},{"issue":"12","key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson's disease.","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"issue":"4","key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"issue":"suppl 2","key":"R27-1-20210203","first-page":"15","article-title":"Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson's disease.","volume":"12","author":"Lewitt","year":"2005","journal-title":"Eur J Neurol"},{"issue":"suppl 1","key":"R28-1-20210203","first-page":"S66","article-title":"Rotigotine transdermal delivery system (TDS) (SPM 962)-a multicenter, double-blind, randomized, placebo-controlled trail to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson's disease.","volume":"7","author":"Quinn","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.","volume":"61","author":"Driver-Dunckley","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.10625","article-title":"Disabling repetitive behaviors in Parkinson's disease.","volume":"19","author":"Kurlan","year":"2004","journal-title":"Mov Disord"},{"issue":"2","key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10072-004-0238-z","article-title":"Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.","volume":"25","author":"Avanzi","year":"2004","journal-title":"Neurol Sci"},{"issue":"3","key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002826-200105000-00009","article-title":"Pathologic gambling in patients with Parkinson's disease.","volume":"24","author":"Gschwandtner","year":"2001","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","article-title":"Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.","volume":"11","author":"Seedat","year":"2000","journal-title":"Depress Anxiety"},{"issue":"1","key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia.","volume":"64","author":"Delong","year":"2007","journal-title":"Arch Neurol"},{"issue":"4","key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1037\/0735-7044.120.4.888","article-title":"Prolonged rewarding stimulation of the rat medial forebrain bundle: neurochemical and behavioral consequences.","volume":"120","author":"Hernandez","year":"2006","journal-title":"Behav Neurosci"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200903000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T15:54:03Z","timestamp":1643990043000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200903000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181684542","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}